Abstract
Purpose
Trastuzumab-based treatment is the standard care for patients with HER2+ metastatic breast cancer (MBC). About 10% of HER2+ MBC showed a long-term durable response (progression-free survival, PFS > 3 years) to trastuzumab-based therapy. The aim of this study is to identify clinico-pathologic factors for a durable response to trastuzumab-based therapy in HER2-positive MBC.
Methods
In the Yonsei Breast Cancer MBC Database, we identified 1218 MBC patients who were diagnosed from 2006 to 2015. Among them, 294 had HER2+ disease, and 153 received trastuzumab plus taxane chemotherapy as first-line treatment. Clinico-pathologic factors, such as hormone receptor (HR) status and metastatic sites, were reviewed. To evaluate a durable response, landmark analysis was performed.
Results
The median follow-up time was 28 months (95% CI 4.4–83.0 months). Of 153 HER2+ patients, there were 73 HR- patients (47.7%), and bone was the most common metastatic site. The median PFS and overall survival (OS) were 12 and 39 months, respectively. HR- patients showed a tendency toward longer PFS (median, 13 vs. 11 months, P = 0.160) compared with HR+ patients. Patients with non-visceral metastases had longer median PFS and OS than those with visceral disease (median PFS, 15 vs. 11 months, P = 0.012; median OS, 75 vs. 34 months, P = 0.03). Landmark analysis at 9 months suggested that the PFS of HR- patients was significantly longer than that of HR+ patients (median, 19 vs. 9 months, P = 0.008).
Conclusions
Among patients with HER2+ MBC, HR status is a possible predictive biomarker of a durable response to trastuzumab-based therapy.
Similar content being viewed by others
References
Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH (2016) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 48(2):436–450. doi:10.4143/crt.2016.089
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423. doi:10.1073/pnas.0932692100
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 7:96. doi:10.1186/1471-2164-7-96
Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412
Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, Ahn JH, Gong G (2014) Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat 145(3):615–623. doi:10.1007/s10549-014-2983-x
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95(2):142–153
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640. doi:10.1016/S0140-6736(11)61847-3
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neo-adjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32. doi:10.1016/S1470-2045(11)70336-9
Santa-Maria CA, Gradishar WJ (2015) Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol 1(4):528–534 (quiz 549). doi:10.1001/jamaoncol.2015.1198
Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J (2012) Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 23(8):2204–2205. doi:10.1093/annonc/mds221
Ascierto PA, Long GV (2016) Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol 17(8):1037–1039. doi:10.1016/S1470-2045(16)30017-1
Ihnenfeld Arcienega I, Imesch P, Fink D, Dedes KJ (2015) Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. Target Oncol 10(2):297–301. doi:10.1007/s11523-014-0350-9
Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nole F (2012) Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 118(1):17–26. doi:10.1002/cncr.26162
Witzel I, Muller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, Janicke F (2014) Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—results from the HER-OS patient registry. BMC Cancer 14:806. doi:10.1186/1471-2407-14-806
Montemurro F, Di Cosimo S, Arpino G (2013) Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol 24(11):2715–2724. doi:10.1093/annonc/mdt287
Hoos A (2016) Development of immuno-oncology —from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15(4):235–247. doi:10.1038/nrd.2015.35
Medina PJ, Adams VR (2016) PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy 36(3):317–334. doi:10.1002/phar.1714
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344(11):783–792. doi:10.1056/Nejm200103153441101
Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205–214. doi:10.1016/j.cell.2015.03.030
Disis ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41(Suppl 5):S3–13. doi:10.1053/j.seminoncol.2014.09.004
Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373(9668):1033–1040. doi:10.1016/S0140-6736(09)60251-8
Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS (2013) First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist 18(5):501–510. doi:10.1634/theoncologist.2012-0414
Acknowledgements
I appreciate the data manager’s help for the collection and analysis of the clinical data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The author(s) have no potential conflicts of interest or financial disclosures.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Park, H.S., Sohn, J., Kim, S.I. et al. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast Cancer Res Treat 163, 255–262 (2017). https://doi.org/10.1007/s10549-017-4175-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4175-y